Virax Biolabs Group Ltd (VRAX) Actualités

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Virax Biolabs Announces Distribution Agreement with Europa Biosite to Commercialize ImmuneSelect in the United Kingdom and Ireland

Virax Biolabs Announces Distribution Agreement with Europa Biosite to Commercialize ImmuneSelect in the United...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 424B5 - Prospectus [Rule 424(b)(5)]

Virax Biolabs Announces Extension of Existing Exclusive Distribution Agreement to Market Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits with Cosmos Health Inc.

Virax Biolabs Announces Extension of Existing Exclusive Distribution Agreement to Market Mpox (formerly...

Virax Biolabs Presents at H.C. Wainwright's 26th Annual Global Investment Conference

Virax Biolabs Presents at H.C. Wainwright's 26th Annual Global Investment Conference PR Newswire LONDON, Sept...

Virax Biolabs to Participate at 7th European Congress of Immunology

Virax Biolabs to Participate at 7th European Congress of Immunology PR Newswire LONDON, Aug. 29, 2024 LONDON...

Virax Biolabs Announces Distribution Agreement to Commercialize Mpox (formerly Monkeypox) Virus RT-PCR Detection Kits in Europe and the Middle East

Virax Biolabs Announces Distribution Agreement to Commercialize Mpox (formerly Monkeypox) Virus RT-PCR...

Virax Biolabs Group Limited Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares

Virax Biolabs Group Limited Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares PR...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 424B5 - Prospectus [Rule 424(b)(5)]

Virax Biolabs Group Limited Announces $5 Million Registered Direct Offering of Ordinary Shares

Virax Biolabs Group Limited Announces $5 Million Registered Direct Offering of Ordinary Shares PR...

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]